established standard of care for patients with advanced hormone receptor-positive breast
cancer. The canonical mechanism underlying CDK4/6 inhibitor activity is the suppression of
phosphorylation of the retinoblastoma tumor suppressor protein, which serves to prevent
cancer cell proliferation. Recent data suggest that these agents induce other diverse effects
within both tumor and stromal compartments, which serve to explain aspects of their clinical …